Monitor for any payment delays or defaults which would trigger immediate 150% repayment obligations and forced conversions at deeply discounted prices, potentially leading to significant share dilution. The high-cost financing suggests liquidity pressure at this micro-cap pharma company.
Price Chart
Executive Summary
IGC Pharma raised $514,000 through two unregistered convertible notes with FirstFire and Vanquish, carrying 12% interest and onerous terms including 75% of the lowest trading price as conversion price and 150% default penalties. The funds are for general working capital, signaling potential distress given the high-cost financing structure.
Key Financial Metrics
Key Facts
- IGC Pharma issued two convertible promissory notes totaling $585,960 principal for $514,000 cash ($307,000 from FirstFire, $207,000 from Vanquish), creating $71,960 in immediate debt via original issue discount
- Notes carry 12% one-time interest and can be converted only upon default at 75% of the lowest trading price over the prior 10 trading days, enabling significant dilution
- Default triggers immediate 150% repayment obligation and conversion rights, with failure to deliver shares incurring $2,000/day penalties
- Proceeds are for general working capital, indicating potential liquidity concerns at the $32M market cap pharmaceutical company
- Both notes contain restrictive covenants limiting asset sales and requiring shareholder approval for large conversions
Financial Impact
Raised $514,000 in immediate capital but created $585,960 in debt with 12% interest and severe default penalties. Conversion at 75% of lowest trading price could lead to substantial shareholder dilution.
Risk Factors
- Severe default terms could lead to 150% repayment obligation or massive dilution through forced conversion
- Conversion at 75% of lowest trading price creates strong downward pressure on stock price
- Multiple high-cost debt issuances may indicate underlying liquidity problems
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001185185-26-001437 |
| Document: igcex10-4.htm | 0001185185-26-001437 |
| Document: igcex10-1.htm | 0001185185-26-001437 |
| Document: igcex10-3.htm | 0001185185-26-001437 |
| Document: igc8k200426.htm | 0001185185-26-001437 |
| Document: 0001185185-26-001437-index-headers.html | 0001185185-26-001437 |
| Document: 0001185185-26-001437-index.html | 0001185185-26-001437 |
| Document: 0001185185-26-001437.txt | 0001185185-26-001437 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | DEFA14A | $0.2434 | awaiting T+60 | — | $0.2500 (+2.71%) |
Oct 21, 2026 4d ago | DEF 14A | $0.2500 | awaiting T+60 | — | $0.2500 (0.00%) |
Jul 6, 2026 15w ago | 8-K | $0.2780 $0.2689 | ▼ −3.27% | ▼ −5.27% | $0.2500 (−10.07%) |
Jun 8, 2026 19w ago | 8-K | $0.2850 $0.2985 | ▲ +4.74% | ▼ −0.16% | $0.2500 (−12.28%) |
Apr 20, 2026 26w ago | 8-K | $0.3200 $0.2563 | ▲ +19.91% | ▲ +26.81% | $0.2500 (+21.88%) |
Mar 12, 2026 32w ago | 8-K | $0.2800 $0.2900 | ▼ −3.57% | ▲ +7.13% | $0.2500 (+10.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers